1.Treatment of pernicious anemia.
Korean Journal of Medicine 2006;71(2):237-240
No abstract available.
Anemia, Megaloblastic
;
Anemia, Pernicious*
;
Vitamin B 12
2.Fighting back against chronic myelomonocytic leukemia.
Blood Research 2013;48(3):165-166
No abstract available.
Leukemia, Myelomonocytic, Chronic
3.Deficiency Anemia.
Journal of the Korean Medical Association 2006;49(10):874-884
Iron deficiency anemia (IDA) and megaloblastic anemia due to vitamin B12 deficiency are well-characterized prototypes of anemia. There is no doubt that IDA is the most common hematologic disorder in Korea and worldwide as well. The diagnosis and treatment of IDA is not a difficult practice usually, however, a caution is required in detecting early-stage iron deficiency and in distinguishing IDA from anemia of chronic disorders such as chronic inflammatory disease, malignancies, chronic liver disease, and chronic renal disease. Administration of a standard iron preparation at a proper dosage over an adequate period is a prerequisite for the successful treatment of IDA, which is sometimes overlooked by both physicians and patients. Early detection and treatment as well as prevention of iron deficiency per se are also required. Pernicious anemia is the most common cause of vitamin B12 deficiency in Western populations. By contrast, the disorder is rare in Korea, although the number of cases seems to be increasing these days. The majority of patients with megaloblastic anemia reveal a history of gastrectomy. Thus, it should be reminded that vitamin B12 supplementation is important to prevent the development of overt deficiency or anemia in these susceptible individuals, since a delay in the treatment of vitamin B12 deficiency may result in an irreversible neurologic deficit.
Anemia*
;
Anemia, Iron-Deficiency
;
Anemia, Megaloblastic
;
Anemia, Pernicious
;
Diagnosis
;
Gastrectomy
;
Humans
;
Iron
;
Korea
;
Liver Diseases
;
Neurologic Manifestations
;
Renal Insufficiency, Chronic
;
Vitamin B 12
;
Vitamin B 12 Deficiency
4.CXCR4 antagonists in hematologic malignancies: more than just mobilizers?.
Korean Journal of Hematology 2011;46(4):209-210
No abstract available.
5.Cutaneous plasmacytoma.
Korean Journal of Hematology 2012;47(3):162-162
No abstract available.
Plasmacytoma
6.Solitary pulmonary plasmacytoma.
Hyewon RYU ; Choongsik LEE ; Deog Yeon JO
Blood Research 2013;48(3):170-170
No abstract available.
Plasmacytoma
7.A case of refractory anemia who obtained hematological remission to cyclosporine therapy.
Jun Young KIL ; Hwan Jung YUN ; Eui Gun CHUN ; Deog Yeon JO ; Samyong KIM ; Jong Wan KIM ; Jong Woo PARK
Korean Journal of Hematology 1992;27(2):317-323
No abstract available.
Anemia, Refractory*
;
Cyclosporine*
8.Fecal Microbiota Transplantation for Treating Steroid-Refractory Acute Graft-versus-Host Disease of the Gut
Sang Hoon YEON ; Myung-Won LEE ; Deog-Yeon JO ; Bu-Yeon HEO ; Jaeyul KWON ; Ik-Chan SONG
Korean Journal of Medicine 2021;96(4):358-362
Restoring the microbiota via fecal microbiota transplantation (FMT) can be an effective treatment for steroid-refractory acute graft-versus-host disease (GVHD) of the gut. Here, we report two adult patients who underwent FMT to treat steroid-refractory acute GVHD of the gut. The first patient was a 43-year-old man who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with cells from a matched sibling donor. The second patient was a 70-year-old woman who underwent haplo-identical HSCT with cells from her son. Gut GVHD developed at 7 and 4 weeks after HSCT, respectively. After undergoing FMT, the clinical symptoms improved; the first patient had a complete response and the second patient had a partial response. Microbial analyses using RNA gene sequencing showed that a diverse fecal microbiome was recovered by 4 weeks after FMT. FMT should be considered an effective therapeutic option for managing steroid-refractory acute GVHD of the gut.
9.Fecal Microbiota Transplantation for Treating Steroid-Refractory Acute Graft-versus-Host Disease of the Gut
Sang Hoon YEON ; Myung-Won LEE ; Deog-Yeon JO ; Bu-Yeon HEO ; Jaeyul KWON ; Ik-Chan SONG
Korean Journal of Medicine 2021;96(4):358-362
Restoring the microbiota via fecal microbiota transplantation (FMT) can be an effective treatment for steroid-refractory acute graft-versus-host disease (GVHD) of the gut. Here, we report two adult patients who underwent FMT to treat steroid-refractory acute GVHD of the gut. The first patient was a 43-year-old man who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with cells from a matched sibling donor. The second patient was a 70-year-old woman who underwent haplo-identical HSCT with cells from her son. Gut GVHD developed at 7 and 4 weeks after HSCT, respectively. After undergoing FMT, the clinical symptoms improved; the first patient had a complete response and the second patient had a partial response. Microbial analyses using RNA gene sequencing showed that a diverse fecal microbiome was recovered by 4 weeks after FMT. FMT should be considered an effective therapeutic option for managing steroid-refractory acute GVHD of the gut.
10.Production of Stromal Cell-Derived Factor-1 (SDF-1)and Expression of CXCR4 in Human Bone Marrow Endothelial Cells.
Journal of Korean Medical Science 2003;18(5):679-685
This study investigated the production of stromal cell-derived factor-1 (SDF-1) and the expression of CXCR4 in human bone marrow endothelial cells (BMECs). Human BMEC cell line BMEC-1 cells expressed SDF-1 mRNA, and conditioned medium induced chemoattraction of CD34+ cells. Migration was not inhibited by pretreating the input cells with pertussis toxin, indicating that the chemoattractive activity was not dependent on SDF-1. Three-day culture of BMEC-1 and primary human BMEC cells produced 1,710+/-204 and 1,050+/-153 pg/mL SDF-1alpha, respectively, which was much less than primary human BM stromal cells (29,536+/-532 pg/ mL). By immuno-histochemistry, CXCR4 was detected in the endothelial cells lining sinusoids, arterioles, and venules in the bone marrow. However, cultured BMECs and BMEC-1 cells did not express CXCR4 on their surfaces. These results indicate that BMECs produce and release small amounts of SDF-1 and express CXCR4 in vivo only.
Antigens, CD34/biosynthesis
;
Bone Marrow Cells/*metabolism
;
Cell Movement
;
Cells, Cultured
;
Chemokines, CXC/*biosynthesis
;
Chemotaxis
;
Culture Media, Conditioned/pharmacology
;
Endothelial Cells/*metabolism
;
Enzyme-Linked Immunosorbent Assay
;
Flow Cytometry
;
Hematopoietic Stem Cells/metabolism
;
Human
;
Immunohistochemistry
;
Pertussis Toxin/pharmacology
;
RNA, Messenger/metabolism
;
Receptors, CXCR4/*biosynthesis
;
Reverse Transcriptase Polymerase Chain Reaction
;
Support, Non-U.S. Gov't
;
Time Factors
;
Umbilical Veins/cytology